DE69803291T2 - Methoden zur verhinderung von knochenresorption - Google Patents

Methoden zur verhinderung von knochenresorption

Info

Publication number
DE69803291T2
DE69803291T2 DE69803291T DE69803291T DE69803291T2 DE 69803291 T2 DE69803291 T2 DE 69803291T2 DE 69803291 T DE69803291 T DE 69803291T DE 69803291 T DE69803291 T DE 69803291T DE 69803291 T2 DE69803291 T2 DE 69803291T2
Authority
DE
Germany
Prior art keywords
use according
alendronic acid
dosing
alendronate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69803291T
Other languages
German (de)
English (en)
Other versions
DE122006000009I1 (de
DE69803291D1 (de
Inventor
Anastasia G Daifotis
Arthur C Santora
A John Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69803291(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69803291D1 publication Critical patent/DE69803291D1/de
Application granted granted Critical
Publication of DE69803291T2 publication Critical patent/DE69803291T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
DE69803291T 1997-07-22 1998-07-17 Methoden zur verhinderung von knochenresorption Revoked DE69803291T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption
PCT/US1998/014796 WO1999004773A2 (en) 1997-07-22 1998-07-17 Method for inhibiting bone resorption

Publications (2)

Publication Number Publication Date
DE69803291D1 DE69803291D1 (de) 2002-02-21
DE69803291T2 true DE69803291T2 (de) 2002-08-08

Family

ID=27451690

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69803291T Revoked DE69803291T2 (de) 1997-07-22 1998-07-17 Methoden zur verhinderung von knochenresorption
DE01201913T Pending DE01201913T1 (de) 1997-07-22 1998-07-17 Methoden zur Hemmung der Knochenresorption
DE01201911T Pending DE01201911T1 (de) 1997-07-22 1998-07-17 Methoden zur Hemmung der Knochenresorption
DE69837450T Expired - Lifetime DE69837450T2 (de) 1997-07-22 1998-07-17 Alendronate zur Behandlung von Osteoporose
DE1998603291 Pending DE122006000009I1 (de) 1997-07-22 1998-07-17 Methoden zur Verhinderung von Knochenresorption
DE200712000063 Pending DE122007000063I1 (de) 1997-07-22 1998-07-17 Alendronate zur Behandlung von Osteoporose

Family Applications After (5)

Application Number Title Priority Date Filing Date
DE01201913T Pending DE01201913T1 (de) 1997-07-22 1998-07-17 Methoden zur Hemmung der Knochenresorption
DE01201911T Pending DE01201911T1 (de) 1997-07-22 1998-07-17 Methoden zur Hemmung der Knochenresorption
DE69837450T Expired - Lifetime DE69837450T2 (de) 1997-07-22 1998-07-17 Alendronate zur Behandlung von Osteoporose
DE1998603291 Pending DE122006000009I1 (de) 1997-07-22 1998-07-17 Methoden zur Verhinderung von Knochenresorption
DE200712000063 Pending DE122007000063I1 (de) 1997-07-22 1998-07-17 Alendronate zur Behandlung von Osteoporose

Country Status (31)

Country Link
EP (5) EP1175904B8 (enExample)
JP (2) JP3479780B2 (enExample)
KR (3) KR20030097611A (enExample)
CN (3) CN1602879A (enExample)
AT (2) ATE357921T1 (enExample)
AU (1) AU8493698A (enExample)
BG (1) BG66282B1 (enExample)
BR (1) BR9810779A (enExample)
CA (1) CA2294595C (enExample)
CY (2) CY1107535T1 (enExample)
DE (6) DE69803291T2 (enExample)
DK (2) DK0998292T3 (enExample)
EA (1) EA004544B2 (enExample)
EE (1) EE05603B1 (enExample)
ES (3) ES2253136T1 (enExample)
HK (4) HK1042230A1 (enExample)
ID (1) ID24096A (enExample)
IL (1) IL133535A0 (enExample)
IS (3) IS5315A (enExample)
LU (2) LU91222I2 (enExample)
NL (2) NL300223I1 (enExample)
NO (1) NO20000323L (enExample)
NZ (1) NZ501807A (enExample)
PL (1) PL195272B1 (enExample)
PT (2) PT998292E (enExample)
SG (2) SG139556A1 (enExample)
SI (1) SI0998292T1 (enExample)
SK (1) SK932000A3 (enExample)
TR (1) TR200000145T2 (enExample)
UY (1) UY25950A1 (enExample)
WO (1) WO1999004773A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3219402B2 (ja) 1998-12-25 2001-10-15 山之内製薬株式会社 多発性骨髄腫の骨病変治療用医薬組成物
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
EP1114642B1 (en) * 1999-07-19 2010-01-06 Toray Industries, Inc. Drugs for periodontal diseases
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
WO2001045636A1 (en) * 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
WO2001076577A2 (en) * 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
DK1296689T3 (da) 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) * 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
AU2004273672A1 (en) * 2003-09-19 2005-03-31 Wisconsin Alumni Research Foundation Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
NZ567200A (en) * 2005-09-16 2010-08-27 Selamine Ltd Bisphosphonate formulation
US9592195B2 (en) * 2010-12-06 2017-03-14 Effrx Pharmaceuticals Sa Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) * 1991-07-01 1995-05-15 Gergely Gerhard Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) * 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
ES2111163T3 (es) * 1992-06-30 1998-03-01 Procter & Gamble Pharma Uso de fosfonatos para el tratamiento de la osteoporosis.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0831843A1 (en) * 1995-06-06 1998-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
DE69726879T2 (de) * 1996-05-17 2004-10-14 Merck & Co., Inc. Biphosphonat-formulierung mit brausewirkung

Also Published As

Publication number Publication date
EP0998292B1 (en) 2001-11-21
JP2002502433A (ja) 2002-01-22
CN1299689C (zh) 2007-02-14
IS5315A (is) 1999-12-21
TR200000145T2 (tr) 2000-05-22
EP1175904A2 (en) 2002-01-30
ATE357921T1 (de) 2007-04-15
JP2005068010A (ja) 2005-03-17
CN1265035A (zh) 2000-08-30
EP1175904B8 (en) 2007-05-09
ID24096A (id) 2000-07-06
PT1175904E (pt) 2007-04-30
EP1175903A3 (en) 2002-12-18
DK1175904T3 (da) 2007-05-07
PL338635A1 (en) 2000-11-06
EE200000040A (et) 2000-10-16
EP1151752A2 (en) 2001-11-07
EP0998292A2 (en) 2000-05-10
NZ501807A (en) 2003-02-28
SK932000A3 (en) 2000-09-12
HK1040494A1 (en) 2002-06-14
EA004544B1 (ru) 2004-06-24
CN1602880A (zh) 2005-04-06
EP1132088A3 (en) 2002-04-24
KR100391732B1 (ko) 2003-07-16
ATE209037T1 (de) 2001-12-15
DE69837450D1 (de) 2007-05-10
SG109478A1 (en) 2005-03-30
KR20030097611A (ko) 2003-12-31
EA200000151A1 (ru) 2000-10-30
BG66282B1 (bg) 2013-01-31
DE122006000009I1 (de) 2006-06-14
EP1175904B1 (en) 2007-03-28
CN1166365C (zh) 2004-09-15
CY2007022I2 (el) 2012-01-25
ES2269014T1 (es) 2007-04-01
DE122007000063I1 (de) 2007-12-20
ES2269014T3 (es) 2007-05-01
AU8493698A (en) 1999-02-16
NO20000323L (no) 2000-03-20
LU91364I2 (fr) 2007-11-12
EP1132088A2 (en) 2001-09-12
DE01201913T1 (de) 2007-02-08
PT998292E (pt) 2002-04-29
IS7230A (is) 2004-04-21
KR20010022110A (ko) 2001-03-15
CA2294595C (en) 2001-08-21
EP1175904A3 (en) 2002-12-18
LU91222I2 (fr) 2006-04-18
ES2253136T1 (es) 2006-06-01
IS7231A (is) 2004-04-21
EA004544B2 (ru) 2006-12-29
NL300292I1 (nl) 2007-11-01
DE69803291D1 (de) 2002-02-21
ES2164447T3 (es) 2002-02-16
HK1024166A1 (en) 2000-10-05
CY2007022I1 (el) 2012-01-25
WO1999004773A2 (en) 1999-02-04
CY1107535T1 (el) 2012-01-25
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
HK1042232A1 (en) 2002-08-09
NL300223I1 (nl) 2006-04-03
PL195272B1 (pl) 2007-08-31
JP3479780B2 (ja) 2003-12-15
SI0998292T1 (en) 2002-04-30
DE69837450T2 (de) 2007-08-23
UY25950A1 (es) 2000-09-29
EP1175903A2 (en) 2002-01-30
BG104093A (en) 2000-10-31
WO1999004773A9 (en) 1999-10-28
WO1999004773A3 (en) 1999-04-15
HK1040495A1 (en) 2002-06-14
KR20030097610A (ko) 2003-12-31
HK1042230A1 (en) 2002-08-09
EP1151752A3 (en) 2002-12-18
IL133535A0 (en) 2001-04-30
CN1602879A (zh) 2005-04-06
DE01201911T1 (de) 2007-10-18
BR9810779A (pt) 2000-07-25
DK0998292T3 (da) 2002-05-13
EE05603B1 (et) 2012-12-17
CA2294595A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
DE69726879T2 (de) Biphosphonat-formulierung mit brausewirkung
DE69837450T2 (de) Alendronate zur Behandlung von Osteoporose
DE60113537T2 (de) Methode zur verabreichung von biphosphonaten
DE69428827T2 (de) Verwendung von Bisphosphorsäurederivaten zur Herstellung eines Medikamentes zur Förderung der Knochenheilung
DE60317061T2 (de) Ibandronsäure zur behandlung und vorbeugung von osteoporose
US20020010161A1 (en) Method for inhibiting bone resorption
DE69526937T2 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE2405254A1 (de) Pharmazeutische oder kosmetische praeparate
EP0521388B1 (de) Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
DE2523998A1 (de) Pharmazeutische zubereitung fuer die behandlung der schizophrenie
DE69534283T2 (de) Clonidinhaltiges arzneimittel mit verzögerter wirkstoffabgabe
DE69833937T2 (de) Verwendung von zinkhyaluronat gegen magengeschwür
WO1999024023A2 (de) FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG
DE60111574T2 (de) Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE69929218T2 (de) Verwendung von biphosphonsaüre derivaten zur herstellung eines arzneimittels zur behandlung von lahmen
DE20321698U1 (de) Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
AT392002B (de) Verwendung von peroxydiphosphaten zur herstellung von pharmazeutischen tabletten bzw. pharmazeutischen waesserigen loesungen
DE19853483A1 (de) Verwendung von Biphosphonaten zur Herstellung von pharmazeutischen Darreichungsformen zur intramuskulären Verwendung
DE60310975T2 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60126638T2 (de) Bisphosphonsäurederivate zur stärkung von kortikalknochen
DE3874982T2 (de) Antipsychotische zusammensetzungen mit dioxopiperidin-derivaten.
DE3424279A1 (de) Verwendung von mini-somatostatinen fuer die behandlung der senilen demenz
DE2030932C3 (de) Arzneimittel zur oralen Behandlung von Oxalatsteinen
DE2532180C2 (de) Verwendung von Etozolin bei der Bekämpfung der Hypertonie

Legal Events

Date Code Title Description
8363 Opposition against the patent
V448 Application of spc

Free format text: PRODUCT NAME: ALENDRONSAEURE (ODER EINER ENTSPRECHENDEN MENGE EINES PHARMAZEUTISCH ANNEHMBARENSALZES DAVON); REGISTRATION NO/DATE: EU/1/05/310/001 - EU/1/05/310/005; 20050824

Spc suppl protection certif: 12 2006 000 009

Filing date: 20060224

V492 Spc regarded as annulled caused by lapse of basic patent

Free format text: PRODUCT NAME: ALENDRONSAEURE (ODER EINER ENTSPRECHENDEN MENGE EINES PHARMAZEUTISCH ANNEHMBARENSALZES DAVON); REGISTRATION NO/DATE: EU/1/05/310/001 - EU/1/05/310/005; 20050824

Spc suppl protection certif: 12 2006 000 009

Filing date: 20060224

R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: VERWENDUNG VON ALENDRONSAEURE ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DAVON, INSBESONDERE VON MONONATRIUMALENDRONAT, GANZ BESONDERS BEVORZUGT VON MONONATRIUMALENDRONAT-TRIHYDRAT, UND VITAMIN D3 (COLECALCIFEROL) ZUR HERSTELLUNG EINES MEDIKAMENTS, DAS 70 MG ALENDRONSAEURE AUF ALENDRONSAEURE-GEWICHTSBASIS ENTHAELT, ZUR WOECHENTLICHEN VERABREICHUNG.; REGISTRATION NO/DATE: EU/1/05/310/001-005 20050824

Spc suppl protection certif: 122006000009

Filing date: 20060224

Expiry date: 20180718

Effective date: 20060404

V492 Spc regarded as annulled caused by lapse of basic patent

Free format text: PRODUCT NAME: ALENDRONSAEURE (ODER EINER ENTSPRECHENDEN MENGE EINES PHARMAZEUTISCH ANNEHMBARENSALZES DAVON); REGISTRATION NO/DATE: EU/1/05/310/001 - EU/1/05/310/005; 20050824

Spc suppl protection certif: 12 2006 000 009

Filing date: 20060224

8339 Ceased/non-payment of the annual fee
8331 Complete revocation
V454 Spc application withdrawn or to be regarded as withdrawn

Free format text: PRODUCT NAME: ALENDRONSAEURE (ODER EINER ENTSPRECHENDEN MENGE EINES PHARMAZEUTISCH ANNEHMBARENSALZES DAVON); REGISTRATION NO/DATE: EU/1/05/310/001 - EU/1/05/310/005; 20050824

Spc suppl protection certif: 12 2006 000 009

Filing date: 20060224